Prognostic Significance of Amplification of the c-MYC Gene in Surgically Treated Stage IB-IIB Cervical Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Mutations of c-MYC have been described in cervical cancer. However, association between c-MYC gene status and its prognostic significance have not been clarified. Methods: Tissue microarray sections from 144 patients with stage IB-IIB cervical cancer treated by radical hysterectomy were analyzed by fluorescence in situ hybridization using a region-specific probe for c-MYC and a centromere-specific probe for chromosome 8. Results: Seventy five percent (108/144) of c-MYC gain and 6.9% (10/144) of c-MYC gene amplification were observed. c-MYC gene alteration was more frequently observed in squamous cell carcinoma than adenocarcinoma or adenosquamous carcinoma and were associated with low Ki67 labeling index (p=0.013). c-MYC amplification was not associated with clinicopathologic parameters except absence of bcl2 expression (p=0.048). Survival analysis revealed that patients with c-MYC amplification were sig-nificantly associated with higher risk of disease recurrence (p=0.007) and cancer related death (p=0.020). However, c-MYC gain was not associated with unfavorable outcome. Multivariate analysis proved c-MYC amplification as independent prognostic factors of shorter disease free survival and cancer-related death (p=0.028 and p=0.025, respectively). Conclusions: c-MYC amplification, not gain, is an independent prognostic marker for shorter disease free and cancer specific survival in cervical cancer treated by radical hysterectomy.
Abstract
Background: Mutations of c-MYC have been described in cervical cancer. However, association between c-MYC gene status and its prognostic significance have not been clarified. Methods: Tissue microarray sections from 144 patients with stage IB-IIB cervical cancer treated by radical hysterectomy were analyzed by fluorescence in situ hybridization using a region-specific probe for c-MYC and a centromere-specific probe for chromosome 8. Results: Seventy five percent (108/144) of c-MYC gain and 6.9% (10/144) of c-MYC gene amplification were observed. c-MYC gene alteration was more frequently observed in squamous cell carcinoma than adenocarcinoma or adenosquamous carcinoma and were associated with low Ki67 labeling index (p=0.013). c-MYC amplification was not associated with clinicopathologic parameters except absence of bcl2 expression (p=0.048). Survival analysis revealed that patients with c-MYC amplification were sig-nificantly associated with higher risk of disease recurrence (p=0.007) and cancer related death (p=0.020). However, c-MYC gain was not associated with unfavorable outcome. Multivariate analysis proved c-MYC amplification as independent prognostic factors of shorter disease free survival and cancer-related death (p=0.028 and p=0.025, respectively). Conclusions: c-MYC amplification, not gain, is an independent prognostic marker for shorter disease free and cancer specific survival in cervical cancer treated by radical hysterectomy.
참고문헌 (30)
- Parkin DM, "Cancer burden in the year 2000. The global picture", Eur J Cancer, 37(Suppl 8), pp.S4~S66 (2001)
- Society of Gynecologic Oncologists Education Resource Panel Writing group, "Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists", Gynecol Oncol, 102, pp.552~562 (2006)
- Querleu D, "Classification of radical hysterectomy", Gynecol Oncol, 115, pp.314~315 (2009)
- Kasamatsu T, "Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation", Gynecol Oncol, 114, pp.69~74 (2009)
- Morley GW, "Radical pelvic surgery versus radiation therapy for stage I carcinoma of the cervix (exclusive of microinvasion)", Am J Obstet Gynecol, 126, pp.785~798 (1976)
- Seo MJ, "New approaches to pathogenic gene function discovery with human squamous cell cervical carcinoma by gene ontology", Gynecol Oncol, 96, pp.621~629 (2005)
- 이아원, "Evaluation of the HPV ISH Assay in Cervical Cancer", The Korean Journal of Pathology, 44(5), pp.513~520 (2010), 대한병리학회
- Peter M, "MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors", Oncogene, 25, pp.5985~5993 (2006)
- Couturier J, "Integration of papillomavirus DNA near myc genes in genital carcinomas and its consequences for proto-oncogene expression", J Virol, 65, pp.4534~4538 (1991)
- Myllykangas S, "Specificity, selection and significance of gene amplifications in cancer", Semin Cancer Biol, 17, pp.42~55 (2007)
- Riou G, "C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix", Lancet, 1, pp.761~763 (1987)
- Berns EM, "c-myc amplification is a better prognostic factor than HER2", neu amplification in primary breast cancer, 1992, pp.52, 1107~1113
- Kallioniemi A, "Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization", Genes Chromosomes Cancer, 12, pp.213~219 (1995)
- Cher ML, "Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer", Genes Chromosomes Cancer, 11, pp.153~162 (1994)
- Zhu H, "High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines", Cancer Lett, 245, pp.303~314 (2007)
- Choschzick M, "Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome", Mod Pathol, 23, pp.603~610 (2010)
- Ruiz C, "Tissue microarrays for comparing molecular features with proliferation activity in breast cancer", Int J Cancer, 118, pp.2190~2194 (2006)
- Koss LG, "The Papanicolaou test for cervical cancer detection: a triumph and a tragedy", JAMA, 261, pp.737~743 (1989)
- Ferlay J, "GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0" (2004), IARC Press
- Zhang A, "Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection", Int J Cancer, 101, pp.427~433 (2002)
- Riou G, "Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers", Oncogene, 3, pp.329~333 (1988)
- Rosty C, "Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation", Mol Cancer, 4, pp.15~ (2005)
- Ferber MJ, "Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma", Oncogene, 22, pp.7233~7242 (2003)
- Hidalgo A, "Human papilloma virus status and chromosomal imbalances in primary cervical carcinomas and tumour cell lines", Eur J Cancer, 36, pp.542~548 (2000)
- Dang CV, "c-Myc target genes involved in cell growth, apoptosis, and metabolism", Mol Cell Biol, 19, pp.1~11 (1999)
- Yuen MF, "Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma", Cancer, 91, pp.106~112 (2001)
- Pelengaris S, "Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression", Cell, 109, pp.321~334 (2002)
- Aoyama C, "Uterine cervical dysplasia and cancer: identification of c-myc status by quantitative polymerase chain reaction", Diagn Mol Pathol, 7, pp.324~330 (1998)
- Smith HO, "The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States: a 24-year population-based study", Gynecol Oncol, 78, pp.97~105 (2000)
- Umanzor J, "Concurrent cisplatin", gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: a phase II trial, 2006, pp.100, 70~75